Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

bio-rad laboratories inc. - BIO

BIO

Close Chg Chg %
328.09 1.19 0.36%

Closed Market

329.28

+1.19 (0.36%)

Volume: 40.54K

Last Updated:

Dec 24, 2024, 12:46 PM EDT

Trade Now

Company Overview: bio-rad laboratories inc. - BIO

BIO Key Data

Open

$323.56

 Day Range

323.56 - 330.27

52 Week Range

262.12 - 386.54

 Market Cap

$9.25B

Shares Outstanding

28.00M

 Public Float

19.17M

Beta

0.90

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$27.28

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

192.10K

  

BIO Performance

1 Week
 
 0.93%
 
1 Month
 
 -2.94%
 
3 Months
 
 -0.37%
 
1 Year
 
 3.05%
 
5 Years
 
 -10.27%
 

BIO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8
Full Ratings ➔

About bio-rad laboratories inc. - BIO

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

BIO At a Glance

Bio-Rad Laboratories, Inc.
1000 Alfred Nobel Drive
Hercules, California 94547
Phone 1-510-724-7000 Revenue 2.67B
Industry Medical Specialties Net Income -637,324,000.00
Sector Health Technology Employees 8,030
Fiscal Year-end 12 / 2024
View SEC Filings

BIO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 3.531
Price to Book Ratio 1.053
Price to Cash Flow Ratio 25.154
Enterprise Value to EBITDA 16.009
Enterprise Value to Sales 3.453
Total Debt to Enterprise Value 0.152

BIO Efficiency

Revenue/Employee 332,660.274
Income Per Employee -79,367.87
Receivables Turnover 5.333
Total Asset Turnover 0.207

BIO Liquidity

Current Ratio 5.831
Quick Ratio 4.338
Cash Ratio 3.085

BIO Profitability

Gross Margin 53.583
Operating Margin 14.368
Pretax Margin -31.824
Net Margin -23.859
Return on Assets -4.94
Return on Equity -6.944
Return on Total Capital -6.281
Return on Invested Capital -6.046

BIO Capital Structure

Total Debt to Total Equity 16.084
Total Debt to Total Capital 13.855
Total Debt to Total Assets 11.431
Long-Term Debt to Equity 15.61
Long-Term Debt to Total Capital 13.448
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Bio-rad Laboratories Inc. - BIO

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
2.55B 2.92B 2.80B 2.67B
Sales Growth
+10.12% +14.81% -4.12% -4.67%
Cost of Goods Sold (COGS) incl D&A
1.11B 1.26B 1.23B 1.24B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
175.20M 173.10M 177.20M 192.40M
Depreciation
147.70M 144.70M 152.30M 168.60M
Amortization of Intangibles
27.50M 28.40M 24.90M 23.80M
COGS Growth
+5.66% +13.26% -1.84% +0.49%
Gross Income
1.44B 1.67B 1.57B 1.43B
Gross Income Growth
+13.84% +16.00% -5.84% -8.74%
Gross Profit Margin
+56.41% +56.99% +55.97% +53.58%
2020 2021 2022 2023 5-year trend
SG&A Expense
1.03B 1.11B 1.09B 1.05B
Research & Development
227.80M 258.36M 256.79M 226.93M
Other SG&A
802.97M 853.47M 832.33M 820.62M
SGA Growth
+2.32% +7.86% -2.04% -3.82%
Other Operating Expense
- - - -
-
Unusual Expense
(4.50B) (4.86B) 5.21B 1.30B
EBIT after Unusual Expense
4.90B 5.41B (4.73B) (911.95M)
Non Operating Income/Expense
27.32M 24.82M 62.78M 111.29M
Non-Operating Interest Income
18.20M 18.90M 58.00M 100.90M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
21.86M 1.55M 38.11M 49.44M
Interest Expense Growth
-6.64% -92.91% +2,357.38% +29.71%
Gross Interest Expense
21.86M 1.55M 38.11M 49.44M
Interest Capitalized
- - - -
-
Pretax Income
4.91B 5.44B (4.70B) (850.10M)
Pretax Income Growth
+117.05% +10.81% -186.51% +81.93%
Pretax Margin
+192.79% +186.08% -167.87% -31.82%
Income Tax
1.10B 1.19B (1.08B) (212.78M)
Income Tax - Current - Domestic
100.07M 77.35M 140.76M 85.80M
Income Tax - Current - Foreign
22.30M 32.60M 24.10M 17.40M
Income Tax - Deferred - Domestic
947.50M 1.05B (1.20B) (331.18M)
Income Tax - Deferred - Foreign
31.50M 32.10M (36.70M) 15.20M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
3.81B 4.25B (3.63B) (637.32M)
Minority Interest Expense
- - - -
-
Net Income
3.81B 4.25B (3.63B) (637.32M)
Net Income Growth
+116.43% +11.55% -185.44% +82.43%
Net Margin Growth
+149.52% +145.28% -129.45% -23.86%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
3.81B 4.25B (3.63B) (637.32M)
Preferred Dividends
- - - -
-
Net Income Available to Common
3.81B 4.25B (3.63B) (637.32M)
EPS (Basic)
127.8644 142.3319 -121.7907 -21.8194
EPS (Basic) Growth
+116.97% +11.31% -185.57% +82.08%
Basic Shares Outstanding
29.77M 29.83M 29.79M 29.21M
EPS (Diluted)
126.2025 140.5556 -121.7907 -21.8194
EPS (Diluted) Growth
+116.60% +11.37% -186.65% +82.08%
Diluted Shares Outstanding
30.16M 30.21M 29.79M 29.21M
EBITDA
580.36M 726.93M 656.52M 576.20M
EBITDA Growth
+35.45% +25.26% -9.69% -12.23%
EBITDA Margin
+22.80% +24.87% +23.43% +21.57%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 397.333
Number of Ratings 8 Current Quarters Estimate 2.87
FY Report Date 12 / 2024 Current Year's Estimate 10.285
Last Quarter’s Earnings 2.01 Median PE on CY Estimate N/A
Year Ago Earnings 11.78 Next Fiscal Year Estimate 11.513
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 6 6 6 6
Mean Estimate 2.87 2.66 10.29 11.51
High Estimates 2.98 3.00 10.39 11.77
Low Estimate 2.68 2.28 10.10 11.20
Coefficient of Variance 3.97 11.54 1.10 1.76

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 4 3
OVERWEIGHT 0 0 1
HOLD 3 3 5
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Bio-rad Laboratories Inc. - BIO

Date Name Shares Transaction Value
Sep 11, 2024 James J. Barry EVP, President, LSG 4,224 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 11, 2024 Sedat Evran EVP, Global Supply Chain 3,456 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 11, 2024 Colleen Corey EVP, Global Human Resources 2,304 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 11, 2024 Allison Schwartz Director 369 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 11, 2024 Melinda Litherland Pei Director 308 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 11, 2024 Courtney C. Enloe EVP, General Counsel & Sec 3,072 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 11, 2024 Michael Crowley EVP, GBL Commercial Operations 3,456 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 11, 2024 Anette Engelhardt EVP, President, CDG 4,608 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 11, 2024 Jeffrey L. Edwards Director 308 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 11, 2024 Arnold A. Pinkston Director 308 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 11, 2024 Norman D. Schwartz Chairman & CEO; Director 13,822 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 11, 2024 Roop Kalyan Lakkaraju EVP, Chief Financial Officer 6,143 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 11, 2024 Gregory K. Hinckley Director 308 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Sep 11, 2024 Andrew J. Last EVP, Chief Operating Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Sep 11, 2024 Andrew J. Last EVP, Chief Operating Officer 7,559 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $329.94 per share 2,494,016.46
Sep 11, 2024 Andrew J. Last EVP, Chief Operating Officer 10,559 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $299.24 per share 3,159,675.16
May 2, 2024 Steven Schwartz 1,498 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $463.86 per share 694,862.28
Mar 13, 2024 Simon May EVP, President, LSG 3,535 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 13, 2024 Timothy S. Ernst EVP, General Counsel & Sec 2,357 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 13, 2024 Sedat Evran EVP, Global Supply Chain 3,535 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Bio-Rad Laboratories Inc. in the News